Islamabad, Nov 01,2026: China’s biotechnology sector is expanding its role in the global pharmaceutical industry, moving beyond the manufacturing of conventional medicines and pharmaceutical ingredients to the development and international licensing of innovative drugs, as growing demand for Chinese-developed therapies creates new opportunities for international research and commercial partnerships.
According to pharmaceutical industry data provider PharmCube, overseas licensing agreements involving Chinese pharmaceutical and biotechnology companies reached a combined potential value of approximately $139.4 billion by October 8, 2026, surpassing the $138.8 billion recorded throughout 2025.
The agreements cover innovative treatments for cancer, obesity and autoimmune diseases, reflecting growing international interest in China’s pharmaceutical research and development capabilities. Upfront payments under these agreements amounted to approximately $8 billion during the first three quarters of 2026.
Major international pharmaceutical companies, including AstraZeneca, GSK and Novo Nordisk, have entered licensing partnerships involving Chinese-developed therapies, highlighting China’s growing importance in global drug discovery and the commercial development of new medicines.
Dr Ijaz Akram, Assistant Professor at the Department of Biotechnology, Institute of Space Technology, told Wealth Pakistan that China’s expanding biotechnology licensing market demonstrated how pharmaceutical competitiveness was increasingly being shaped by research, clinical development and intellectual property rather than manufacturing capacity alone.
“Pakistan can benefit from closer cooperation with Chinese companies through specialised manufacturing, technology transfer and joint research programmes,” he said.
The growing value of overseas licensing agreements reflects a broader transformation in China’s pharmaceutical industry, with domestic companies increasingly developing innovative therapies and securing commercial partnerships with international drug manufacturers.
According to China’s Ministry of Industry and Information Technology, the potential value of overseas licensing agreements involving innovative Chinese medicines exceeded $100 billion during the first half of 2026.
The ministry also reported that China approved 38 innovative medicines for marketing during the same period, including 31 developed by domestic companies, indicating the country’s growing capabilities in pharmaceutical research and product development.
In September 2026, Chinese authorities outlined further plans to strengthen the biomedical industry, with an emphasis on innovative medicines, biotechnology research and international competitiveness.
The expansion of China’s pharmaceutical innovation sector is creating opportunities for developing economies to establish partnerships in drug research, specialised manufacturing, technology transfer and clinical development.
For Pakistan, closer cooperation with Chinese biotechnology companies could provide an opportunity to move beyond importing medicines and pharmaceutical raw materials towards developing domestic research capabilities and higher-value pharmaceutical products.
Dr Ijaz Akram said Pakistan should prioritise partnerships that strengthen local technical expertise rather than limiting cooperation to the importation or packaging of finished pharmaceutical products.
“Technology-transfer agreements should include workforce training, research collaboration and the development of local production capabilities. This would help Pakistani pharmaceutical companies gradually move towards higher-value products and improve their prospects in international markets,” he said.
He added that cooperation with Chinese pharmaceutical companies could help Pakistan gradually develop expertise in specialised manufacturing and research-based pharmaceutical production, provided such partnerships included meaningful knowledge transfer and technical training.
The growing international demand for innovative medicines also highlights the importance of strong research institutions, clinical-trial capabilities and regulatory systems in supporting pharmaceutical development.
Talking to Wealth Pakistan, Fatima Ayub, Researcher at the Department of Pharmaceutical Sciences, Hamdard University, said Pakistan could benefit from China’s progress in biotechnology by developing stronger links between pharmaceutical companies, universities and research institutions.
“Pakistan has opportunities to collaborate with Chinese biotechnology institutions in drug discovery, clinical research and advanced pharmaceutical development. However, these partnerships will require reliable clinical-trial systems, internationally recognised quality standards and sustained investment in scientific expertise,” she said.
Fatima emphasised that international pharmaceutical cooperation should focus on building long-term scientific and technological capabilities rather than relying solely on short-term commercial arrangements.
“Joint research laboratories, researcher exchanges and collaborative clinical development programmes could help Pakistan strengthen its biotechnology ecosystem. The objective should be to create the capacity to develop and commercialise pharmaceutical innovations locally,” she added.
She said stronger collaboration between academic institutions and pharmaceutical manufacturers could help translate scientific research into commercially useful products while improving the skills and experience of local researchers.
China’s expanding role in international pharmaceutical licensing also demonstrates the growing commercial importance of intellectual property and research-led innovation in the global medicines market.
Unlike conventional pharmaceutical exports, licensing agreements allow drug developers to commercialise their research through international partners, potentially generating upfront payments, milestone revenues, and royalties as medicines progress toward the market.
However, the reported $139.4 billion represents the combined potential value of licensing agreements, including payments linked to future development and commercial milestones, rather than revenue already received by Chinese companies.
For Pakistan, China’s transformation offers an opportunity to strengthen pharmaceutical cooperation through joint research, technology transfer, workforce development and specialised manufacturing.
The country’s ability to benefit from these opportunities will depend on sustained investment in scientific expertise, internationally recognised regulatory standards and partnerships that support the development of domestic pharmaceutical innovation.
